Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMost people notice reduced appetite within the first one to four weeks of starting Wegovy. Meaningful, measurable weight loss typically begins in weeks two to six, though the pace varies by dose, diet, and individual biology. Wegovy (semaglutide) is a prescription-only medicine; a clinician must assess your suitability before treatment starts.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Wegovy's prescribed starting dose is 0.25mg weekly. At this level, the medicine's job is to let your body acclimatise to a GLP-1 receptor agonist — slowing gastric emptying, steadying appetite signals, reducing the nausea that a faster ramp-up would otherwise cause. Some people do see the scale move during this month; many don't, and that's expected. What you'll more likely notice is that you feel full sooner and think about food less. That shift is real and it matters, even if the number hasn't changed yet. Keep the pen in the fridge door where you'll see it each morning, consistency with the weekly dose is more important at this stage than anything else. If you're curious about how quickly Wegovy will work for you personally, that page walks through the realistic expectations week by week. For a broader look at how the medicine works mechanically, the Wegovy overview page covers the GLP-1 pathway in detail.
Side effects are most common in these early weeks: nausea, loose stools, or mild indigestion after eating. They typically settle within days to a fortnight. If they don't, your prescriber needs to know before any dose change.
The licensed titration schedule moves through 0.5mg, then 1.0mg, then 1.7mg, each held for roughly four weeks. As the dose climbs, the appetite-suppressing effect deepens. This is the period when most people start logging consistent weekly losses, often 0.5 to 1 kg per week when combined with a reduced-calorie diet and more movement. The rate isn't linear. Some weeks the scale barely shifts; the following week it drops more than expected. That's normal physiology, not a sign the medicine has stopped working. Patience through a plateau matters more than switching doses early. You can read more about the early timeline at how quickly Wegovy starts working, which covers what to expect in those opening weeks.
This is also the phase where the practical habit of the weekly injection usually becomes routine, easy enough to fit around an existing weekly anchor, whether that's a Monday morning or a Friday evening.
At 2.4mg weekly (or, for some patients now, up to the MHRA-approved 7.2mg dose via the dedicated single-dose pen approved in April 2026), weight loss continues at a steadier rate. The STEP 1 trial, published in the New England Journal of Medicine, followed 1,961 adults with obesity over 68 weeks: those receiving 2.4mg semaglutide lost an average of around 15% of body weight, compared with roughly 2.4% on placebo, alongside lifestyle changes. That figure is an average across the whole trial population, some participants lost more, some less.
For most people the bulk of total weight loss occurs in the first year. Progress tends to slow after around 60 to 68 weeks as a new physiological equilibrium is reached. Stopping the medicine without a plan usually sees weight return, which is why ongoing clinical review matters. How long Wegovy takes to work overall explores what determines that longer arc. The NICE appraisal of semaglutide (TA875) recommends treatment within a structured weight management programme, noting that less than 5% weight loss after six months at the maintenance dose is a signal to reassess. That's a clinical judgement, not a reason to panic, but it is something to discuss with your prescriber rather than work through alone.
Wegovy works alongside a reduced-calorie diet and increased physical activity; it isn't a substitute for them. People who use the reduced appetite actively (eating enough protein, staying hydrated, keeping up strength exercise) tend to see better fat-loss outcomes and lose less lean mass. Genetics, starting weight, gut physiology, and how consistently the injection is taken each week all influence pace. There's no reliable way to predict in advance exactly how quickly any individual will respond. What the trial data does confirm is that a real clinical effect exists and that it builds over months, not days. Questions about your specific rate of progress, whether a plateau warrants a dose change, or how the schedule fits your circumstances are exactly what our prescribers are there to answer, see how quickly you lose weight on Wegovy for more on individual variation. If you want to understand how cost fits into the picture before you commit, the Wegovy cost and access page sets out what private treatment typically involves.
Wegovy is a prescription-only medicine. A GPhC-registered Independent Prescriber (a real clinician, reading your answers) reviews every consultation at nume before any treatment is issued. If you're ready to find out whether you're suitable, speak to our prescribers through a free consultation today.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.